What is it about?
To understand how CoQ0, the novel analog without isoprenoid side chains, inhibits Lipopolysaccharide (LPS)-induced inflammation through the modulation of nuclear factor κB (NFκB)/activator protein 1 (AP-1) and NF-E2 related factor 2 (Nrf2) signalling pathways. The finding further emphasizes that CoQ0-mediated suppression of NFκB/AP-1 activation is associated with the inhibition of LPS-induced Reactive Oxygen Species (ROS) accumulation in macrophages
Featured Image
Why is it important?
This finding supports that the CoQ0-induced NFκB suppression and Nrf2 activation are led by decreased inflammatory mediators in LPS-stimulated macrophages. It confirms that CoQ0 could modulate LPS-induced inflammatory responses
Perspectives
Past report shows that matrine, an alkaloid found in plants from the genus Sophora, could attenuate LPS-induced acute lung injury partially through inhibition of NFκB signalling. This is the first report that shows CoQ0, a key ingredient in Antrodia camphorata, can demonstrate the anti-inflammatory properties through suppression of NFκB and/or activation Nrf2 in mice against LPS challenge. Such additional finding provides an opportunity to develop a novel therapeutic drugs to treat inflammatory disorder
Dr. You-cheng Hseu
China Medical University
Read the Original
This page is a summary of: Coenzyme Q 0 regulates NFκB/AP-1 activation and enhances Nrf2 stabilization in attenuation of LPS-induced inflammation and redox imbalance: Evidence from in vitro and in vivo studies, Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms, February 2016, Elsevier,
DOI: 10.1016/j.bbagrm.2015.11.001.
You can read the full text:
Resources
Contributors
The following have contributed to this page
